Please use this identifier to cite or link to this item: http://dl.umsu.ac.ir/handle/Hannan/275968
Title: Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells
Authors: Vannes, Victoria Lee;Trivedi, Mahendra Kumar;Branton, Alice;Trivedi, Dahryn;Nayak, Gopal;Mondal, Sambhu Charan;Jana, Snehasis
subject: The Trivedi effect®;Biofield energy treatment;Cardiac health;Liver health;Lungs health;VDR receptor;Brain health;Bone health
Year: 19-Jul-2019
Publisher: SMGroup
Citation: Victoria Lee Vannes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, and Snehasis Jana. Evaluation of the Impact of the Biofield Energy Treated Test Formulation on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells. SM J Public Health Epidemiol. 2019; 5(2): 1053.
Abstract: Vital organs dysfunctions are the major concern for human health worldwide. The study aim was to investigate the impact of Biofield Treated test formulation on vital organs function using cell-based assays. The test formulation/test item (TI) and cell media (Med) was divided into two parts; one untreated (UT) and other part received the Biofield Treatment remotely by a renowned Biofield Energy Healer, Victoria Lee Vannes, USA and was labeled as Biofield Treated (BT) test formulation/media. Based on the cell viability test formulation was found safe in six different cells. The test formulation groups showed 112.6% and 108.65% restoration of cell viability in human cardiac fibroblasts cells (HCF); while, 845.63% restoration of cell viability in human hepatoma cells (HepG2) compared to UT-Med + UT-TI group. Furthermore, 131.86% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) than untreated. The alkaline phosphatase (ALP) level was significantly increased by 94.87%, 99.06%, and 105.13% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) than untreated. Additionally, ALP level was significantly increased by 150.97%, 382.08%, and 471.4% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) than untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 115.1% (1 µg/mL) and 165.77% (10 µg/mL)in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 117.65% (1 µg/mL) and 91.3% (63 µg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively than untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 40.56% in UT-Med + BT-TI at 10 µg/mL than untreated. Serotonin level was significantly increased by 543.84% (1 µg/mL), 477.12% (10 µg/mL), and 457.22% (10 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively than untreated. The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 186.96%, 341.43%, and 291.31% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 1 µg/mL than untreated. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Therefore, the Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.
URI: https://www.trivedieffect.com/science/evaluation-of-the-impact-of-the-biofield-energy-treated-test-formulation-on-various-biomarkers-in-human-bones-heart-liver-lungs-and-brain-cells/
http://dl.umsu.ac.ir/handle/Hannan/275968
ISSN: 2473-0661
Appears in Collections:منابع مشترک



Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.